about
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous miceDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusmTOR inhibitors in advanced renal cell carcinomaRole of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacksGenome-environment interactions that modulate aging: powerful targets for drug discoveryTargeting the mTOR kinase domain: the second generation of mTOR inhibitorsNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyThe PI3K pathway as drug target in human cancerThe pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsOlive Oil and the Hallmarks of AgingThe fate of chemoresistance in triple negative breast cancer (TNBC)Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumorsTargeting the mTOR signaling pathway in neuroendocrine tumorsDifferentiating mTOR inhibitors in renal cell carcinomaObesity in cancer survivalTargeting translation initiation in breast cancerAdvances in the treatment of relapsed or refractory Hodgkin's lymphomaPTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activationRole of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerPDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascademTOR signaling in tumorigenesisThe N-terminal region of p27 inhibits HIF-1α protein translation in ribosomal protein S6-dependent manner by regulating PHLPP-Ras-ERK-p90RSK axisCurcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stabilityNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancerColocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.High-resolution characterization of a hepatocellular carcinoma genome.A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy.Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.Activation of the AMP-activated protein kinase-p38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53-mutant mouse mammary tumor cells.Metformin: a therapeutic opportunity in breast cancer.Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further ProposalsLkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).Investigational agents in development for the treatment of ovarian cancerPhase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
P2860
Q24597354-CC0DBE15-4600-4FEE-8069-A3ED77E91CECQ24600932-E2E11DC0-1BF9-4E13-84F9-CDF86378A6F5Q24612127-737F3ABC-7801-4A85-853D-88C6D03CCD99Q24612235-19DEB672-7124-4806-A90C-43FE183EE34DQ24615803-E709A8EC-29C1-4A2A-BA84-DA1AD061EA24Q24622194-D513A6B3-0CF2-48C6-AC2A-C77FBF3C9D35Q24628724-E6757337-2414-4934-8D77-3FB45869C433Q24632283-FFADB6A3-CCBC-401C-B53C-7AE94E713034Q26740374-5288E8E0-9735-44B3-889D-6EEF66D2BF49Q26769864-8D2E72FE-2B47-4FB1-BC0C-0A67F7A586F9Q26775232-8B334F08-E566-465F-AFB6-C1B537F8D3E2Q26823873-1ABA4BA7-62B2-4D6B-ADBA-CFB6BA627799Q26852089-3900313E-D850-4999-B232-CD340094629BQ26860172-276AF2A7-123E-416F-9739-7A4BF66C203FQ26863606-90752635-6700-47C6-A4FE-E41DA61452CFQ27027284-5428ED81-336C-4B0E-8E27-CD3A59D1449DQ27694504-24864EDB-0582-4F31-BFBC-3FB4B103FD56Q27852528-95728A1D-81D7-4BE5-8749-601515D33DF4Q28075965-03A0CD60-F1FB-41C7-BC09-9F15C9544B43Q28246822-E15085BB-8F78-465C-8AF5-77F2F8052598Q28252695-84CC4B74-93D9-4912-A88B-566C2B40C5DFQ28383901-E64EF32D-F81E-48AC-A625-CC8BA7F3ED41Q28538024-9BF6AF1D-04C9-46CB-AB55-1FAADF167401Q30364864-BB0AC987-C457-4002-B8A7-07821EA79D57Q30430510-972EAB6B-AE91-4A33-84E7-63E43F043B46Q30583249-06C6EE9A-6262-4753-B297-D4904FCAF1E0Q31005512-EC60D3FC-3D02-40D1-86EF-D7DBBB9F2A6FQ33401450-2F834D66-CFB6-4966-B4A4-D358FF243A4BQ33422258-5E2D6F87-4F9F-4D76-BE09-93DD0208D2DEQ33642278-E0134D82-ADBB-4674-918C-50675898E982Q33652827-3062FCD8-2B0E-4127-BF41-D6B808C81B45Q33683126-97DF8AC0-3E91-4A30-BAC4-740AFB9942B3Q33727103-F28D9B68-A886-4B3E-BDB0-8999B95FBD67Q33733319-85924BBB-AB7B-45A6-ACD1-00D99B05A642Q33739267-53AA9779-E75B-49AB-9656-B01677E3D744Q33760578-BFC3B525-D6C8-4CE3-9DB5-BA8215F50473Q33849248-5858BC67-0151-44E9-A567-751129D41E05Q33861319-BDB04A82-2BC8-4CC4-B078-B53373A6DDABQ33920800-D1F78EE4-DF98-446D-9AC8-C27D75B1746FQ33921891-999473B4-786D-408C-9310-63D538E6F7D6
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Targeting the mTOR signaling network for cancer therapy
@ast
Targeting the mTOR signaling network for cancer therapy
@en
Targeting the mTOR signaling network for cancer therapy
@nl
type
label
Targeting the mTOR signaling network for cancer therapy
@ast
Targeting the mTOR signaling network for cancer therapy
@en
Targeting the mTOR signaling network for cancer therapy
@nl
prefLabel
Targeting the mTOR signaling network for cancer therapy
@ast
Targeting the mTOR signaling network for cancer therapy
@en
Targeting the mTOR signaling network for cancer therapy
@nl
P2860
P3181
P356
P1476
Targeting the mTOR signaling network for cancer therapy
@en
P2093
Ana Maria Gonzalez-Angulo
P2860
P304
P3181
P356
10.1200/JCO.2008.20.0766
P407
P577
2009-05-01T00:00:00Z